glp 1 ra Visual representation of the beneficial roles of GLP-1RA in Frontiers | Exploring the multifaceted

Whether you are dealing with rheumatoid arthritis (RA), psoriatic arthritis (PsA), lupus (SLE), Sjgrens disease (SD), or even osteoarthritis (OA), chronic inflammation keeps the immune system in a constant attack mode, leading to: Pain Swelling Stiffness Mobility problems Tissue and cartilage damage This chronic, ongoing inflammation not only makes joints hurt more, but it will worsen blood sugar control, fatigue, brain fog, and increase the risk of heart disease

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone

For a deeper look at vascular and cardiometabolic risk, see our pages on Preventive Cardiology and Silent Heart Disease Detection, Metabolic Health and Longevity Medicine, and ApoB and Longevity

The study found that the risks of these adverse outcomes was similar with or without GLP-1 exposure during the first trimester

These mechanisms are central to restoring function in type 2 diabetes as in that condition glucose does not stimulate adequate Ca 2+ influx

In the case of the PPAR- agonist drugs, the most widely anticipated additional benefit was decreased vascular disease because of favorable effects of the drug class on risk factors for vascular disease supported by murine studies reporting protection against ischemic heart disease (3)